Biotechnology cancer

Study Identifies Subtype of Triple Negative Breast Cancer That Responds Better to Chemotherapy

Researchers at Yale Cancer Center have identified a new subtype of triple negative breast cancer that shows significantly improved response to chemotherapy. Patients with the newly defined “BRCA deficient” subtype experienced better survival with chemotherapy. The study was published on Dec. 13 in PLOS Medicine. Triple negative breast cancer (TNBC) disproportionately affects younger women and […]